All In Biotech

Drug Trial Radar · NCT00240929

A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)

A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis), A Humanized Respiratory Syncytial Virus Monoclonal Antibody, in Children With a History of Prematurity

Last checked: Nov 20, 2026Latest source record: Nov 15, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Actual

Start

Sep 2002

Primary completion

Not stated

Study completion Apr 2003

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 18, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 5 months, up to 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A total of 150 children who meet the entry criteria will be randomized 1:1 to receive one of the following treatment sequence A or B.

Conditions

  • -Unhealthy Children With a History of Prematurity

Interventions

  • MEDI-493Drug

    Active Comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. adverse events through 30 days after each injection of study drug and will have blood collected for determination of palivizumab concentrations in serum.Time frame: Day 30

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Packard Children's Hospital at Stanford

    Palo Alto, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.